Dr. Zorn discusses the Optilume BPH System

In this video, Kevin C. Zorn, MD, FRCSC, FACS, discusses the Optilume BPH Catheter System, which was granted FDA approval in July 2023 for the treatment of patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH). The Optilume device was also highlighted at the recent SoBPD 2024 Annual Meeting in Dallas, Texas. Zorn is a urologist and the founder of BPH Canada in Montreal.

Video Transcript:

The one that's the new kid on the block and that's recently FDA approved and that are starting up different centers offering it is what's called first in treatment. There's MISTs, there's maximal therapies, there's laser therapies, and now this idea of a balloon encoated with a special drug that will create an opening within the prostate. So, rather than putting in artificial materials–stents, lasers, or surgeries where we create a lot of inflammation–can we simply go in with a cystoscope and pass through over a guide wire a balloon? Then just rotating a wrist, balloon dilating out for 5-10 minutes under some form of anesthesia. The results that we've seen from the PINNACLE (NCT04131907) and the EVEREST (NCT03423979) trial for this Optilume BPH device, now with Laborie, is unheard of. If you look at the Qmax, the flow rate pattern, that we're seeing with this compared to Rezum, iTind, or the UroLift, it's unprecedented. So, I really am excited to see that. The indications are pretty broad, so you can treat a wide variety of patients. And it's in access with a regular flexible cystoscope. You don't need special bronchoscopes or extra equipment; it's going to simply be the device with a balloon that's encoated with paclitaxel. Pretty straightforward, no thermal issues, a catheter maybe for a day or 2, and take it out. The recovery is a lot faster than we see perhaps with Rezum or some of the other procedures, so [it’s] exciting. We learned from Dr. Kaplan at the meeting is that there’s unique CPT codes and there's no global period for this, something that's also favorable for the physician. It's not just favorable economically in certain environments, but also has great data to support it. It's exciting to see that we now have another offering to men with enlarged prostates that has good outcomes and good durability up to 5 years [based on] the trials.

This transcription has been edited for clarity.